EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non–small-cell Lung Cancer

Janna Schoenmaekers, Jeanet Dijkstra, Anthonie van der Wekken, Marthe Paats, Martijn Broen, Lloyd Brandts, Anne-Marie Dingemans, Lizza Hendriks

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2023.12.003 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Janna Schoenmaekers und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Diseases, GROW - School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Lactams, Pyrazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Longfonds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Lorlatinib is a potent, brain penetrant, next-generation ALK/ROS1 TKI, with high response rates and durable responses, including the brain. However, a significant drawback is the manifestation of neurocognitive adverse events (NCAEs). Despite being generally low-grade in severity, these NCAEs can be physically and mentally disabling. Extensive neurocognitive testing in this group of patients is lacking; therefore we conducted this study. PATIENTS AND METHODS: This observational prospective study was conducted across 3 Dutch university hospitals. Patients with metastatic NSCLC with an ALK- or ROS1-rearrangement and having an indication to start lorlatinib in daily clinical practice were eligible. The primary endpoints were to identify changes in neurocognitive functioning, measured through neurocognitive assessment at intervals of 2 weeks and 2 months after starting lorlatinib, in comparison to baseline. As a secondary endpoint, the correlation between neurocognitive impairment and self-reported neurocognitive dysfunction was examined. RESULTS: Between June 2019 and October 2022, 22 patients were included. Among the various neurocognitive tests administered, only the Hopkins Verbal Learning Test-Revised parts b and c demonstrated a significant and clinically relevant decrease in scoring 2 weeks post initiation of lorlatinib (P = .036 and P = .003, respectively). However, these returned to baseline at the 2-month evaluation. The questionnaires did not result in significantly different outcomes over time. CONCLUSION: Lorlatinib treatment did not result in a sustained and significant decline within any of the specified neurocognitive domains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsLactamsPyrazolesHumansProtein-Tyrosine KinasesProspective StudiesAnaplastic Lymphoma KinaseProto-Oncogene ProteinsAminopyridinesLactams, MacrocyclicProtein Kinase Inhibitors

Stichwörter der Autor:innen

LorlatinibMoodNSCLCNeurocognitionNeurocognitive testing

Substanzen

lorlatinibProtein-Tyrosine KinasesAnaplastic Lymphoma KinaseProto-Oncogene ProteinsAminopyridinesLactams, MacrocyclicProtein Kinase InhibitorsLactamsPyrazoles

Autor:innen und Institutionen

  • Department of Pulmonary Diseases, GROW - School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Department of Medical Psychology, Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Department Pulmonary Diseases, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
  • Department of Neurology, Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center +, Maastricht, the Netherlands.

Förderung

  • Longfonds

Zitieren

APA

Schoenmaekers, J., Dijkstra, J., van der Wekken, A., Paats, M., Broen, M., Brandts, L., Dingemans, A. M., & Hendriks, L. (2024). In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non–small-cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2023.12.003

Vancouver

Schoenmaekers J, Dijkstra J, van der Wekken A, Paats M, Broen M, Brandts L, et al. In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non–small-cell Lung Cancer. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2023.12.003

BibTeX
@article{Schoenmaekers2024,
  author = {Schoenmaekers, Janna and Dijkstra, Jeanet and van der Wekken, Anthonie and Paats, Marthe and Broen, Martijn and Brandts, Lloyd and Dingemans, Anne-Marie and Hendriks, Lizza},
  title = {In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non–small-cell Lung Cancer},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2023.12.003}
}
Kostenlos starten →